Acute coronary syndrome in the patient with diabetes: Is the management different?

Amit P. Amin, Steven P. Marso

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Diabetic patients who present with an acute coronary syndrome (ACS) have a particularly adverse prognosis, largely contributed by increased platelet reactivity and higher burden of disease severity. Diabetic patients with ACS derive a greater benefit from established therapies, particularly platelet-inhibiting therapies, including clopidogrel pretreatment, and glycoprotein IIb/IIIa inhibitor use. Recent data show intense ADP-P2Y12 platelet receptor inhibition with prasugrel is of particular clinical value in the diabetic patient with ACS, without excessive bleeding. Diabetic patients with ACS also benefit more from aggressive revascularization strategies. Recent data show the benefit of drug-eluting stents in the setting of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in decreasing target vessel revascularization up to 2 years, particularly in patients at highest risk for restenosis with bare metal stents (likely diabetic patients). This review summarizes the data supporting the key pharmacologic and revascularization management strategies to guide the clinician in taking care of diabetic patients who present with an ACS event.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalCurrent Cardiology Reports
Volume12
Issue number4
DOIs
StatePublished - Jul 2010

Fingerprint

Acute Coronary Syndrome
Blood Platelets
clopidogrel
Platelet Glycoprotein GPIIb-IIIa Complex
Drug-Eluting Stents
Percutaneous Coronary Intervention
Adenosine Diphosphate
Stents
Patient Care
Metals
Hemorrhage
Therapeutics

Keywords

  • Acute coronary syndrome
  • Antiplatelet agents
  • Clopidogrel
  • Diabetes mellitus
  • Drug-eluting stents
  • Percutaneous coronary intervention
  • Prasugrel
  • Revascularization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Acute coronary syndrome in the patient with diabetes : Is the management different? / Amin, Amit P.; Marso, Steven P.

In: Current Cardiology Reports, Vol. 12, No. 4, 07.2010, p. 321-329.

Research output: Contribution to journalArticle

@article{8cce9e454f414fbabfb27e8a1e5f2b19,
title = "Acute coronary syndrome in the patient with diabetes: Is the management different?",
abstract = "Diabetic patients who present with an acute coronary syndrome (ACS) have a particularly adverse prognosis, largely contributed by increased platelet reactivity and higher burden of disease severity. Diabetic patients with ACS derive a greater benefit from established therapies, particularly platelet-inhibiting therapies, including clopidogrel pretreatment, and glycoprotein IIb/IIIa inhibitor use. Recent data show intense ADP-P2Y12 platelet receptor inhibition with prasugrel is of particular clinical value in the diabetic patient with ACS, without excessive bleeding. Diabetic patients with ACS also benefit more from aggressive revascularization strategies. Recent data show the benefit of drug-eluting stents in the setting of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in decreasing target vessel revascularization up to 2 years, particularly in patients at highest risk for restenosis with bare metal stents (likely diabetic patients). This review summarizes the data supporting the key pharmacologic and revascularization management strategies to guide the clinician in taking care of diabetic patients who present with an ACS event.",
keywords = "Acute coronary syndrome, Antiplatelet agents, Clopidogrel, Diabetes mellitus, Drug-eluting stents, Percutaneous coronary intervention, Prasugrel, Revascularization",
author = "Amin, {Amit P.} and Marso, {Steven P.}",
year = "2010",
month = "7",
doi = "10.1007/s11886-010-0118-5",
language = "English (US)",
volume = "12",
pages = "321--329",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Acute coronary syndrome in the patient with diabetes

T2 - Is the management different?

AU - Amin, Amit P.

AU - Marso, Steven P.

PY - 2010/7

Y1 - 2010/7

N2 - Diabetic patients who present with an acute coronary syndrome (ACS) have a particularly adverse prognosis, largely contributed by increased platelet reactivity and higher burden of disease severity. Diabetic patients with ACS derive a greater benefit from established therapies, particularly platelet-inhibiting therapies, including clopidogrel pretreatment, and glycoprotein IIb/IIIa inhibitor use. Recent data show intense ADP-P2Y12 platelet receptor inhibition with prasugrel is of particular clinical value in the diabetic patient with ACS, without excessive bleeding. Diabetic patients with ACS also benefit more from aggressive revascularization strategies. Recent data show the benefit of drug-eluting stents in the setting of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in decreasing target vessel revascularization up to 2 years, particularly in patients at highest risk for restenosis with bare metal stents (likely diabetic patients). This review summarizes the data supporting the key pharmacologic and revascularization management strategies to guide the clinician in taking care of diabetic patients who present with an ACS event.

AB - Diabetic patients who present with an acute coronary syndrome (ACS) have a particularly adverse prognosis, largely contributed by increased platelet reactivity and higher burden of disease severity. Diabetic patients with ACS derive a greater benefit from established therapies, particularly platelet-inhibiting therapies, including clopidogrel pretreatment, and glycoprotein IIb/IIIa inhibitor use. Recent data show intense ADP-P2Y12 platelet receptor inhibition with prasugrel is of particular clinical value in the diabetic patient with ACS, without excessive bleeding. Diabetic patients with ACS also benefit more from aggressive revascularization strategies. Recent data show the benefit of drug-eluting stents in the setting of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in decreasing target vessel revascularization up to 2 years, particularly in patients at highest risk for restenosis with bare metal stents (likely diabetic patients). This review summarizes the data supporting the key pharmacologic and revascularization management strategies to guide the clinician in taking care of diabetic patients who present with an ACS event.

KW - Acute coronary syndrome

KW - Antiplatelet agents

KW - Clopidogrel

KW - Diabetes mellitus

KW - Drug-eluting stents

KW - Percutaneous coronary intervention

KW - Prasugrel

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=77956394853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956394853&partnerID=8YFLogxK

U2 - 10.1007/s11886-010-0118-5

DO - 10.1007/s11886-010-0118-5

M3 - Article

C2 - 20446120

AN - SCOPUS:77956394853

VL - 12

SP - 321

EP - 329

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 4

ER -